May 2, 2019 10:40 AM EDTUpdated 01:39 PM
Financing
R&D

Weeks af­ter a Pfiz­er/Mer­ck KGaA break­down, Clo­vis gam­bles on a $175M loan to fin­ish a glob­al PhI­II PARP/PD-1 com­bo study

John Carroll

Editor & Founder

Clo­vis On­col­o­gy CEO Patrick Ma­haffy $CLVS has en­gi­neered a risky gam­ble to pay for his big Phase III study com­bin­ing his PARP Rubra­ca with Bris­tol …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times